Roles of FGF signaling in skeletal development and human genetic diseases
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Fibroblast growth factor receptors (FGFRs) exist as a gene family of 4 membrane bound receptor tyrosine kinases (FGFR1-4) that mediate signals of at least 22 fibroblast growth factors (FGF1-22). FGFs/FGFRs play important roles in multiple biological processes, including mesoderm induction and patterning, cell growth and migration, organ formation and bone growth. Furthermore, it has been shown that missense mutations of FGFR1-3 in human result in, at least, 14 congential bone diseases that are broadly classified into two groups: chondrodysplasia syndromes and craniosynostosis syndromes. The chondrodysplasia affects primarily the skeleton formed through endochondral ossification, resulting short-limbed dwarfisms, while the craniosynostosis affects mainly bones formed through intramembraneous ossification, leading to premature fusion of the craniofacial sutures. Using gene targeting, mouse models mimicking some of these human diseases have been created. Analysis of these mutant mice revealed essential functions of FGFs/FGFRs in skeletal development and maintenance. These models may be beneficial in future studies aimed at developing novel therapeutic strategies for FGFR-related skeletal dysplasias. In this review, we discuss the results of recent studies on FGF receptors to illustrate mechanisms through which the abnormally activated FGF/FGFR signaling results in these diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Osf2/Cbfa1: A Transcriptional Activator of Osteoblast Differentiation
Ducy, P., Zhang, R., Geoffroy, V., Ridall, A. L., & Karsenty, G. (1997) · Cell · doi:10.1016/s0092-8674(00)80257-3 · Cited by 4,246
Fibroblast growth factors, their receptors and signaling
Powers, C. J., McLeskey, S. W., & Wellstein, A. (2000) · Endocrine-related cancer · doi:10.1677/erc.0.0070165 · Cited by 1,332
Sprouty1 and Sprouty2 provide a control mechanism for the Ras/MAPK signalling pathway
Hanafusa, H., Torii, S., Yasunaga, T., & Nishida, E. (2002) · Nature Cell Biology · doi:10.1038/ncb867 · Cited by 566 · cited 7×
“It was therefore proposed that the principal difference between FGFR1, 3, and 4 is the strength (or intensity) of the tyrosine kinase activity, but not the qualitative differences in signaling capacity, i.e. FGFR1, 3, and 4 might have similar signaling pathways, primarily FRS2 and, perhaps, PLC-γ (17).”
BackgroundInfluentialDisruption of the fibroblast growth factor-2 gene results in decreased bone mass and bone formation
Montero, A., Okada, Y., Tomita, M., Ito, M., Tsurukami, H., Nakamura, T., Doetschman, T., Coffin, J. D., & Hurley, M. M. (2000) · Journal of Clinical Investigation · doi:10.1172/jci8641 · Cited by 483 · cited 1×
“FGF2 expression was found both in growth plate chondrocytes and periosteoblasts of the long bones, but FGF2deficient mice showed only mild decrease in bone mass without obvious abnormality in chondrogenesis (43).”
BackgroundManagement of craniosynostoses
Renier, D., Lajeunie, E., Arnaud, E., & Marchac, D. (2000) · Child s Nervous System · doi:10.1007/s003810000320 · Cited by 384
Iseki, S., Wilkie, A. O. M., & Morriss-Kay, G. M. (1999) · Development · doi:10.1242/dev.126.24.5611 · Cited by 305
Cited by
FGF/FGFR signaling in health and disease
Xie, Y., Su, N., Yang, J., Tan, Q., Huang, S., Jin, M., Ni, Z., Zhang, B., Zhang, D., Luo, F., et al. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00222-7 · Cited by 904
Signaling and transcriptional regulation in osteoblast commitment and differentiation
Huang, W. (2007) · Frontiers in Bioscience · doi:10.2741/2296 · Cited by 649
Zhu, S., Chen, W., Masson, A., & Li, Y.-P. (2024) · Cell Discovery · doi:10.1038/s41421-024-00689-6 · Cited by 463
Kinase mutations in human disease: interpreting genotype–phenotype relationships
Lahiry, P., Torkamani, A., Schork, N. J., & Hegele, R. A. (2010) · Nature Reviews Genetics · doi:10.1038/nrg2707 · Cited by 420
Fibroblast growth factor signaling in skeletal development and disease
Ornitz, D. M., & Marie, P. J. (2015) · Genes & Development · doi:10.1101/gad.266551.115 · Cited by 418
Regulation of osteogenic differentiation during skeletal development
Deng, Z.-L. (2008) · Frontiers in Bioscience · doi:10.2741/2819 · Cited by 343
Development of the upper lip: Morphogenetic and molecular mechanisms
Jiang, R., Bush, J. O., & Lidral, A. C. (2006) · Developmental Dynamics · doi:10.1002/dvdy.20646 · Cited by 339
Role of FGF/FGFR signaling in skeletal development and homeostasis: learning from mouse models
Su, N., Jin, M., & Chen, L. (2014) · Bone Research · doi:10.1038/boneres.2014.3 · Cited by 290
Self-citationLi, C., Scott, D. A., Hatch, E., Tian, X., & Mansour, S. L. (2007) · Development · doi:10.1242/dev.02701 · Cited by 273
Fibroblast growth factor (FGF) signaling in development and skeletal diseases
Teven, C. M., Farina, E. M., Rivas, J., & Reid, R. R. (2014) · Genes & Diseases · doi:10.1016/j.gendis.2014.09.005 · Cited by 237
Jacob, A. L., Smith, C., Partanen, J., & Ornitz, D. M. (2006) · Developmental Biology · doi:10.1016/j.ydbio.2006.05.031 · Cited by 200
“Mutations in FGFRs account for many of the craniosynostosis and chondrodysplasia syndromes in humans (Chen and Deng, 2005; Morriss-Kay and Wilkie, 2005; Ornitz, 2005; Ornitz and Marie, 2002).”
BackgroundSignaling Networks that Control the Lineage Commitment and Differentiation of Bone Cells
Soltanoff, C. S., Yang, S., Chen, W., & Li, Y.-P. (2009) · Critical Reviews™ in Eukaryotic Gene Expression · doi:10.1615/critreveukargeneexpr.v19.i1.10 · Cited by 197
Kadam, S., McMahon, A., Tzou, P., & Stathopoulos, A. (2009) · Development · doi:10.1242/dev.027904 · Cited by 83
“At least 15 human genetic diseases result from mutations within FGFR genes and each disease is caused by a different mutation shown to affect receptor activation (Chen and Deng, 2005).”
Background
Metadata
- Authors
- Chen, L.
- Venue
- Frontiers in Bioscience
- Publisher
- IMR Press
- Published
- 2005
- Volume
- 10
- Issue
- 1-3
- Pages
- 1961
- ISSN
- 1093-4715 (ISSN-L)
- 1093-9946
- DOI
- 10.2741/1671
- OpenAlex
- W1530921588
- Cited by
- 93
- References
- 6
- FWCI
- 2.77
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.